Neil P. Shah
Affiliations: | Biomedical Sciences | University of California, San Francisco, San Francisco, CA |
Area:
Oncology, Immunology, Cell BiologyGoogle:
"Neil Shah"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jabbour E, Apperley J, Cortes J, et al. (2024) Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia |
| Winn AN, Atallah E, Cortes J, et al. (2023) Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. Jama Network Open. 6: e2347950 |
| Wang X, DeFilippis RA, Weldemichael T, et al. (2023) An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L. European Journal of Medicinal Chemistry. 264: 115977 |
| Wang X, DeFilippis RA, Leung YK, et al. (2023) N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants. Bioorganic Chemistry. 143: 106966 |
| Kantarjian HM, Jabbour E, Deininger M, et al. (2022) Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. American Journal of Hematology |
| Zhang L, Lakkaniga NR, Bharate JB, et al. (2021) Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. European Journal of Medicinal Chemistry. 225: 113776 |
| Smith CC, Viny AD, Massi E, et al. (2021) Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Atallah E, Schiffer CA, Radich JP, et al. (2020) Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. Jama Oncology |
| Mali RS, Zhang Q, DeFilippis R, et al. (2020) Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica |
| Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. (2019) Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leukemia & Lymphoma. 1-10 |